KYNB earnings date and last-quarter result: next report 2026-08-10, last quarter miss, P/E 0.17. Updated 2026-07-23.
Kyntra Bio (KYNB) Research Hub
Kyntra Bio (KYNB) trades on NASDAQ, US in the Healthcare (Medical - Pharmaceuticals) sector. As of 2026-10-26, shares last closed at 4.5 USD (-1.75%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 0.17, market cap 0.03B. This hub links to the full technical, earnings and options research available for KYNB.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Medical - Pharmaceuticals) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 4.5 USD (-1.75%) |
| 52-week range | 4.36 USD – 8.67 USD |
| Trend regime | Range |
| 14-day RSI | 25.7 (Oversold) |
| Trailing P/E | 0.17 |
| Market cap | 0.03B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for KYNB
Covered Call on KYNB: how it works, illustrative setup around the real 4.5 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on KYNB: how it works, illustrative setup around the real 4.5 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on KYNB: how it works, illustrative setup around the real 4.5 USD price, max profit/loss, breakeven and when to use it. Educational.
KYNB technical analysis: range, last 4.5 USD, RSI 25.7, 52w range 4.36 USD–8.67 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is KYNB in?
Kyntra Bio (KYNB) is classified under Healthcare (Medical - Pharmaceuticals), listed on NASDAQ, US.
Is KYNB in an uptrend or downtrend?
As of 2026-10-26, KYNB is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is KYNB's trailing P/E ratio?
KYNB's trailing P/E is 0.17, with a market cap of 0.03B. See the earnings research page for full valuation detail.
When does KYNB next report earnings?
KYNB is next scheduled to report earnings on 2026-08-10.